论文部分内容阅读
目的 :对存在初治菌阳肺结核(简称TIT)患者予以吡嗪酰胺(简称Pza)耐药治疗,探析实际治疗效果。方法 :选取2014年3月到2015年7月之间存在TIT的76例患者作为实际研究对象,对上述76例患者予以药敏实验,在此基础上给予患者有效分组,将对Pza敏感的TIT40例患者划分为是实验组,将对Pza耐药的TIT36例患者划分为是对照组,相关医护人员给予两组患者Pza实际治疗并对比两组患者实际治疗效果。结果 :实验组中40例Pza敏感的TIT患者实际转阴率集中在92.5%(37/40),而对照组36例Pza耐药的TIT患者实际转阴率为55.5%(20/36);此外实验组患者X线吸收方面实际好转率集中在90.0%(36/40),对照组患者X线吸收方面实际好转率集中在52.7%(19/36)。两组对比具有统计学意义,p<0.05。结论 :对Pza敏感的TIT患者予以Pza药物治疗能够取得较好的治疗效果,不仅能够将患者痰菌实际转阴率予以有效提高,而且还能够将患者实际X线吸收方面实际好转率予以良好提高。
OBJECTIVE: To treat pyrazinamide (referred to as Pza) in patients with newly diagnosed bacillary positive pulmonary tuberculosis (TIT) for the purpose of exploring the actual therapeutic effect. Methods: Sixty-six patients with TIT between March 2014 and July 2015 were selected as the actual study subjects. The drug susceptibility test was performed on the above 76 patients. On the basis of this, effective patients were divided into groups and the PIT-sensitive TIT40 The patients were divided into experimental groups. Twenty-three TITs resistant to Pza were divided into two groups: the control group, the relevant medical staff to give the actual treatment of Pza and the actual treatment effect of the two groups. Results: The actual negative conversion rates of the 40 patients with Pza - sensitive TIT were 92.5% (37/40) in the experimental group, while that of the 36 patients with Pza - resistant TIT in the control group was 55.5% (20/36). In addition, the actual improvement rate of X-ray absorption in experimental group was 90.0% (36/40), while the actual improvement rate of X-ray absorption in control group was concentrated in 52.7% (19/36). The two groups were statistically significant, p <0.05. Conclusion: The Pza-responsive treatment of Pza-sensitive TIT patients can achieve better therapeutic effect, which can not only effectively increase the actual negative conversion rate of sputum bacteria, but also improve the actual improvement rate of actual X-ray absorption of patients .